Prior studies have shown that FnBPA5 can serve in animal models as a fibronectin‐targeting radiotracer for the SPECT/CT imaging of prostate cancer.[68, 110] Thus, future strategies might introduce mechano‐regulated interventions, such as FnBPA5‐drug conjugates, to selectively target the mechanically altered ECM in MVPs. This evidence concerns the gene FN1 and prostate cancer.